Eli Lilly breaks ground on $6.5B Houston plant to boost pharmaceutical production

Eli Lilly has commenced construction on a $6.5 billion pharmaceutical manufacturing plant in northeast Houston, marking a significant expansion of the city's life sciences sector. The 236-acre facility, located in Generation Park, will produce active pharmaceutical ingredients, including for Foundayo, Lilly's oral GLP-1 weight-loss drug. This project is being hailed as a milestone for Texas, with Governor Greg Abbott describing it as the largest active pharmaceutical ingredient initiative in the state’s history. The plant highlights Houston's growing importance in healthcare and pharmaceutical manufacturing and is scheduled for completion by 2030.

AI-generated from public news sources. Not financial advice.